Panelists discuss how health care providers can optimize quality-of-life and treatment outcomes for patients with myelofibrosis through comprehensive symptom management, shared decision-making, and ...

SBS acknowledges the Traditional Custodians of Country and their connections and continuous care for the skies, lands and ...

Ten days of subcutaneous Dacogen resulted in responses among a third of patients with myelofibrosis. Among patients with ...

Panelists discuss how myelofibrosis progresses from its molecular and genetic origins through various clinical manifestations ...

In patients with myelofibrosis, clearance of driver mutations at day 30 after transplantation appeared to influence relapse and survival, irrespective of the underlying driver mutation.

One retrospective analysis of 91 patients with AML arising from myelofibrosis showed a median survival of just 2.6 months from the time of leukemic transformation. Risk of Progression "This form ...

Around 100,000 Australians live with a rare form of blood cancer, and a new treatment approved by the medicines watchdog is ...

It can be used in both markets in patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis. In the pivotal MOMENTUM clinical ...

“Upon diagnosis, intermediate-1 and -2 and high-risk myelofibrosis patients typically receive ruxolitinib as the primary therapy, which reduces enlarged spleens and alleviates symptoms. These ...